Почетна › Рабидомиосарком › Тексас
Kliničke studije za Рабидомиосарком u državi Тексас
9 studija za Рабидомиосарком traži učesnike na lokacijama u državi Тексас.
Gradovi u državi Тексас
Zvanični tekst studije (na engleskom)
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Children's Medical Center, Dallas
Тражи се учесникФаза 1/2
До 30 година · Оба пола · Ажурирано 12. 11. 2026. · NCT06541262Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- University of Texas - MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
24 Months – 18 Years · Оба пола · Ажурирано 27. 10. 2026. · NCT06441331Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
- UT Southwestern, Dallas
- Texas Tech University Health Sciences Center, Lubbock
Тражи се учесникФаза 1
12 Months – 20 Years · Оба пола · Ажурирано 8. 10. 2026. · NCT02013336PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Texas Children's Hospital, Houston
Тражи се учесникФаза 1/2
Узраст од 1 до 30 · Оба пола · Ажурирано 6. 10. 2026. · NCT06721689A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- и још 2
Тражи се учесникФаза 3
До 50 година · Оба пола · Ажурирано 25. 8. 2026. · NCT07466316Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
- Texas Children's Hospital, Houston
Тражи се учесникФаза 1
Узраст од 1 до 21 · Оба пола · Ажурирано 6. 8. 2026. · NCT04715191Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
- Cook Children's Medical Center, Fort Worth
Тражи се учесникФаза 2
До 22 година · Оба пола · Ажурирано 15. 6. 2026. · NCT06023641HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
- Texas Children's Hospital, Houston
Тражи се учесникФаза 1
Узраст од 1 до 25 · Оба пола · Ажурирано 22. 1. 2026. · NCT04995003Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
- Houston Methodist Hospital, Houston
Тражи се учесникФаза 1
До 21 година · Оба пола · Ажурирано 3. 11. 2025. · NCT06198296Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.